XTX Topco’s Sarepta Therapeutics SRPT Stock Holding History

XTX Topco’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Buy	+13,224	New	+$256K	0.01%	2520
2025 Q3	–	Sell	-31,808	Closed	-$544K	–	3235
2025 Q2	$544K	Buy	+31,808	New	+$1.36M	0.02%	1032
2024 Q3	–	Sell	-4,578	Closed	-$723K	–	2586
2024 Q2	$723K	Buy	+4,578	New	+$588K	0.06%	489
2022 Q1	–	Sell	-2,495	Closed	-$225K	–	933
2021 Q4	$225K	Buy	+2,495	New	+$213K	0.13%	324
2021 Q2	–	Sell	-8,643	Closed	-$644K	–	1076
2021 Q1	$644K	Buy	+8,643	New	+$798K	0.31%	44

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XTX Topco's SRPT Position: Q1 2026 in Review

XTX Topco opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 13,224 shares worth $288K. The stake represents 0.01% of the portfolio and ranks #2520 among its holdings. This is a return to the name: XTX Topco previously reported a position in SRPT as recently as Q2 2025.

XTX Topco first reported a position in SRPT in Q1 2021 and has held it in 5 quarters since. The position peaked at $723K in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

XTX Topco held 13,224 shares of Sarepta Therapeutics worth $288K as of Q1 2026.
Sarepta Therapeutics was a new XTX Topco position in Q1 2026.
Sarepta Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2520 holding.
XTX Topco first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 5 quarters since.
XTX Topco's Sarepta Therapeutics position peaked at $723K in Q2 2024.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.